相关实验视频
Updated: Jun 12, 2025

11:51
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
11.9K
作为抗癌剂的奎诺林-2H-one混合物的治疗潜力
Naik Soniya1,2, Vasu Soumya1, Mamle Desai Shivlingrao1
1Department of Pharmaceutical Chemistry, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, 600116, India.
Mini reviews in medicinal chemistry
|September 26, 2024
概括
癌症的发病率不断增加,迫使人们发现新的药物. 昆-2-杂交物显示出作为抗癌药物的前景,与目前的治疗方法相比,具有提高疗效和减少副作用的潜力.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 全球癌症病例正在上升,目前的治疗方法显示生存率有限.
- 现有的化疗药物缺乏最佳的疗效,推动了对新型治疗剂的需求.
- 分子杂交是一种新兴的策略,用于设计新的抗癌药物.
研究的目的:
- 审查作为潜在的抗癌剂的林-2-one杂交物.
- 探索各种林-2-衍生物的抗癌性质和机制.
- 确定开发有效的新型抗癌药物的结构性要求.
主要方法:
- 对林-2-一混合物及其抗癌活性研究的文献综述.
- 对Tipifarnib和Dovitinib等现有的抗癌药物的分析.
- 检查不同的异环基架与林-2-one结合.
主要成果:
- 昆-2-one杂交体显示出针对各种癌症细胞系的显著抗癌潜力.
- 奇诺林-2-one与像pyrone,pyrrole和pyrimidine这样的支架的组合显示出有希望的结果.
- 蒂皮法尼布和多维蒂尼布是成功使用的二甲基抗癌剂的例子.
结论:
- 昆二混合物代表了一类有前途的化合物,用于开发新型抗癌药物.
- 对结构修改的进一步研究可能会导致具有增强有效性和安全性特征的药物.
- 本综述为设计基于二基架的下一代抗癌疗法提供了洞察力.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K

